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Olanzapine-activated AMPK signaling in the dorsal vagal complex is
attenuated by histamine H1 receptor agonist in female rats
Abstract
Weight gain and its related metabolic disorders are major side-effects associated with second generation
antipsychotic drug (SGA) treatment. The dorsal vagal complex (DVC) and AMP-activated protein kinase
(AMPK) are implicated in the regulation of food intake and body weight. Blocking the histamine H1 receptor
(H1R) contributes to antipsychotic-induced weight gain. The present study investigated the time-dependent
effect of olanzapine treatment (8, 16 and 36 days) on DVC AMPK signaling in olanzapine-induced weight
gain, and whether these changes are associated with olanzapine-induced H1 receptor antagonism. During the
8-day olanzapine treatment the rats were hyperphagic and rapidly gained weight. The phosphorylation of
AMPK (pAMPK: activated AMPK) as well as its directly downstream phospho-Acetyl-CoA carboxylase
(pACC) was significantly increased. The pAMPK/AMPK ratio, an indicator of AMPK activity, was
significantly positively correlated with feeding efficiency and weight gain. As treatment was prolonged (16 and
36-day olanzapine treatment), the rats were no longer hyperphagic, and there were no longer any changes in
DVC AMPK signaling. Although the DVC H1R protein expression was not significantly altered by
olanzapine, the pAMPK expression was significantly positively correlated with the H1R level after the 8, 16,
and 36-day olanzapine treatments. Moreover, we showed that an H1R agonist, 2-(3-trifluoromethylphenyl)
histamine, significantly inhibited the olanzapine-induced hyperphagia and DVC AMPK activation in a dose-
dependent manner. These results suggest a time-dependent role of DVC AMPK in olanzapine-induced
obesity. Thus, olanzapine-induced DVC AMPK activation may be at least partially related to olanzapine's
antagonistic effect on the H1R.
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Olanzapine-Activated AMPK Signaling in the Dorsal
Vagal Complex Is Attenuated by Histamine H1
Receptor Agonist in Female Rats
Meng He, Qingsheng Zhang, Chao Deng, Hongqin Wang, and Xu-Feng Huang
Centre for Translational Neuroscience (M.H., Q.Z., C.D., H.W., X.-F.H.), School of Medicine and Illawarra
Health and Medical Research Institute, University of Wollongong, Wollongong 2522, New South Wales,
Australia; and Schizophrenia Research Institute (C.D., X.-F.H.), Darlinghurst 2010, New South Wales,
Australia
Weight gain and its related metabolic disorders are major side effects associated with second
generation antipsychotic drug treatment. The dorsal vagal complex (DVC) and AMP-activated
protein kinase (AMPK) are implicated in the regulation of food intake and body weight. Blocking
the histamine H1 receptor contributes to antipsychotic-induced weight gain. The present study
investigated the time-dependent effect of olanzapine treatment (8, 16, and 36 d) on DVC AMPK
signaling in olanzapine-induced weight gain and whether these changes are associated with olan-
zapine-induced H1 receptor antagonism. During the 8-day olanzapine treatment, the rats were
hyperphagic and rapidly gained weight. The phosphorylation of AMPK (pAMPK) (activated AMPK)
as well as its directly downstream phospho-acetyl-coenzyme A carboxylase was significantly in-
creased. The pAMPK/AMPK ratio, an indicator of AMPK activity, was significantly positively cor-
related with feeding efficiency and weight gain. As treatment was prolonged (16 and 36 d of
olanzapine treatment), the rats were no longer hyperphagic, and there were no longer any
changes in DVC AMPK signaling. Although the DVC H1 receptor protein expression was not sig-
nificantly altered by olanzapine, the pAMPK expression was significantly positively correlated with
the H1 receptor level after the 8-, 16-, and 36-day olanzapine treatments. Moreover, we showed
that an H1 receptor agonist, 2-(3-trifluoromethylphenyl) histamine, significantly inhibited the
olanzapine-induced hyperphagia and DVC AMPK activation in a dose-dependent manner. These
results suggest a time-dependent role of DVC AMPK in olanzapine-induced obesity. Thus, olan-
zapine-induced DVC AMPK activation may be at least partially related to olanzapine’s antagonistic
effect on the H1 receptor. (Endocrinology 155: 4895–4904, 2014)
Second generation antipsychotic drug (SGA) treatment,in particular olanzapine and clozapine, can cause se-
rious weight gain and other metabolic problems (1). In
recent years, multiple contributors have been identified to
be involved in antipsychotic-induced weight gain, such as
the histaminergic H1 and H3 receptors, serotonin 2C, do-
paminergic D2, muscarinic M3, and the adrenergic- re-
ceptors (reviewed in Refs. 2–4). Moreover, neuropeptide
Y (NPY), proopiomelanocortin (POMC) (5, 6), and cen-
tral ghrelin signaling (7) have also been reported to con-
tribute to olanzapine-induced obesity. However, the exact
cellular mechanisms that promote SGA-induced weight
gain are not fully understood.
The dorsal vagal complex (DVC), comprising the nu-
cleus of the tractus solitarius (NTS), dorsal motor nucleus
of the vagus, and area postrema, is well known for medi-
ating appetite by responding to satiety signals. The NTS
integrates the signals between the hypothalamus and the
gut to regulate food intake (8). The dorsal motor nucleus
of the vagus, located ventral to the NTS and containing
ISSN Print 0013-7227 ISSN Online 1945-7170
Printed in U.S.A.
Copyright © 2014 by the Endocrine Society
Received April 18, 2014. Accepted September 24, 2014.
First Published Online September 29, 2014
Abbreviations: ACC, acetyl-CoA carboxylase; AMPK, AMP-activated protein kinase; BAT,
brown adipose tissue; DVC, dorsal vagal complex; FMPH, 2-(3-trifluoromethylphenyl) his-
tamine; icv, intracerebroventricular; NPY, neuropeptide Y; NTS, nucleus of the tractus
solitarius; O/F(H), olanzapine/FMPH 200 nmol; pAMPK, phospho-AMPK; POMC, proopio-
melanocortin; SD, Sprague-Dawley; SGA, second generation antipsychotic drug; V/S,
vehicle/saline.
N E U R O E N D O C R I N O L O G Y
doi: 10.1210/en.2014-1326 Endocrinology, December 2014, 155(12):4895–4904 endo.endojournals.org 4895
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 30 January 2015. at 07:56 For personal use only. No other uses without permission. . All rights reserved.
primary efferents to regulate the gut, is involved in medi-
ating food intake (9). Therefore, an imbalance of the sys-
tems in the DVC that mediate food intake can lead to
obesity and other metabolic disorders.
AMP-activated protein kinase (AMPK), is a sensor of
cellular energy status, which is activated by the cellular
AMP/ATP ratio and upstream kinases (10). AMPK in the
central nervous system plays an important role in the reg-
ulation of energy balance, food intake, and body weight in
mammals (11, 12). AMPK in the NTS has been reported
to mediate food intake (13, 14). AMPK activity in the NTS
increases in food-deprived rats and is abolished by refeed-
ing (14). The injection of the APMK inhibitor, Compound
C, into the fourth ventricle and NTS reduces food intake
(14). Previous studies in rats have reported that the DVC
is involved in mediating olanzapine-induced weight gain
(15, 16). However, whether DVC AMPK signaling plays
a role in mediating olanzapine-induced food intake and
weight gain is unknown.
Clinical evidence has indicated that SGA induces
weight gain (in particular olanzapine and clozapine) in a
time-dependent manner. In the first 3 months, patients
experienced a rapidly increased body weight (early stage);
during 3–18 months, the rate of weight gain decreased
(middle stage); and finally, after 18 months, weight pla-
teaued at a heavy level and was maintained with continu-
ing antipsychotic treatment (late stage) (17, 18). Similar
effects have been found in the animal model, although
each period is shorter (7, 19). The evidence suggests that
the mechanisms that promote olanzapine-induced weight
gain at different stages may vary. Does the DVC AMPK
signaling play a different role in the different stages of
olanzapine-induced obesity?
Olanzapine and clozapine have been reported to acti-
vate hypothalamic AMPK (20–23). Clozapine’s activa-
tion of AMPK is significantly linked to its antagonistic
effect on the H1 receptors (23). However, it is not known
whether the effect of olanzapine on the DVC AMPK sig-
naling is also linked to the antagonism of the central H1
receptors. The present study provides evidence for the first
time that olanzapine treatment activates AMPK signaling
in the DVC in a time-dependent manner and that this effect
is related to olanzapine-induced weight gain. Further-
more, we tested whether DVC AMPK activation could be
modulated by central H1 receptor activation and its rela-
tionship with olanzapine-induced hyperphagia.
Materials and Methods
Animals, drugs, and chemicals
Female Sprague-Dawley (SD) rats (weight 200–225 g) were
obtained from the Animal Resources Centre. The rats were
housed under environmentally controlled conditions (22°C on a
12-h light, 12-h dark cycle; lights on 7 AM). Rats were allowed ad
libitum access to food and water throughout the studies. All of
the animal experiments were approved by the Animal Ethics
Committee, University of Wollongong, and complied with the
Australian Code of Practice for the Care and Use of Animals for
Scientific Purposes (2004). Olanzapine (Zyprexa) was obtained
from Eli Lilly. 2-(3-trifluoromethylphenyl) histamine (FMPH)
and pyrilamine were obtained from Sigma-Aldrich (Sigma).
Experiment 1
To investigate the role of DVC AMPK signaling and H1 re-
ceptors at different stages of olanzapine-induced weight gain, we
conducted this experiment to detect changes in AMPK signaling
and the H1 receptors under olanzapine treatment for 8, 16, and
36 days. Briefly, SD rats were randomly divided into 3 groups
(n  12/group) and fed with sweet cookie dough pellets (62%
carbohydrate, 22% protein, 6% fiber, and 10% vitamins and
minerals) mixed with either olanzapine (1 mg/kg) or placebo 3
times daily at 8-hour intervals at 7 AM, 3 PM, and 11 PM (7). We
measured food intake and body weight every 48 hours. At the
end of treatment, all rats were euthanized between 9 AM and 11
AM by CO2 asphyxiation 2 hours after the last drug treatment.
The DVC were quickly dissected on ice, frozen in liquid nitrogen,
and then stored at 80°C. Postmortem white adipose tissue
(perirenal, periovary, inguinal, and omental fat) and liver were
dissected and individually weighed.
Experiment 2
To determine the effect of energy intake restriction on olan-
zapine-induced weight gain and whether changes in the DVC
AMPK signaling were a secondary effect of elevated food intake
and body weight gain induced by olanzapine, we conducted a
pair-feeding experiment for 8 days similar to experiment 1 (8-d
treatment cohort). Rats were randomly divided into 2 groups
(n  12/group) and treated with olanzapine or vehicle as de-
scribed in experiment 1. All of the rats in both groups (olanzapine
and control) received restricted food intake (80% of the control
group based on previous measurements) (7). Body weight was
measured every 2 days. Rats were killed, and the DVC was col-
lected using the same procedure as experiment 1.
Experiment 3
To further investigate whether DVC AMPK signaling is
linked to olanzapine’s antagonistic effect on the central H1 re-
ceptors and olanzapine-induced hyperphagia, the olanzapine-
treated rats received an intracerebroventricular (icv) injection of
an H1 receptor agonist, FMPH. Briefly, after acclimatization for
1 week, SD rats were implanted with a 24-gauge guide cannula
into the lateral ventricle under isoflurane anesthesia (1.0 mm
posterior to the bregma, 1.5 mm lateral to the midline, and 3.5
mm below the top skull) (24). After recovery for 1 week, the rats
were orally treated with olanzapine or vehicle (same as in ex-
periment 1) for 4 days. On day 5, the rats were given an icv 100
or 200 nmol injection of the H1 receptor agonist, FMPH, or
saline as a control (in 5 L, at a rate of 5 L/min) (25) (n 
5–8/group: group 1, vehicle/saline [V/S]; group 2, vehicle/FMPH
200 nmol; group 3, olanzapine/saline; group 4, olanzapine/
FMPH 100 nmol; group 5, olanzapine/FMPH 200 nmol [O/
F(H)]). Thirty minutes later, the rats were orally treated with
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olanzapine or vehicle. We measured the food intake of the rats at
1, 2, 4, 16, and 24 hours after the olanzapine or vehicle were
given. Before measuring food intake, rats were allowed ad libi-
tum access to food and water. To check whether the effect of
FMPH on food intake could be attenuated by the H1 receptor
antagonism, another group was injected with pyrilamine, an H1
receptor antagonist, by icv 30 minutes before the FMPH was
given (group 6, O/F(H)/pyrilamine 800 nmol). The same treat-
ment was repeated after a 3-day drug washout period, and the
rats were killed 1 hour after their last treatment (between 12 PM
and 2 PM) using CO2 asphyxiation. The DVC nuclei were im-
mediately dissected on ice, frozen in liquid nitrogen, and then
stored at 80°C.
Western blotting
Western blotting was conducted following the procedure in
Ref. 26. The DVC tissues were homogenized using Nonidet P40
cell lysis buffer (Life Technologies) containing -glyceropho-
shate, a protease inhibitor cocktail, and phenylmethanesulfonyl
fluoride (Sigma). The protein concentration was detected by DC
protein assay (Bio-Rad Laboratories). A total of 15- to 25-g
proteins were loaded onto 4%–12% Bis-Tris gels (Bio-Rad Lab-
oratories) and run for 50 minutes at 200 V. The proteins were
transferred to polyvinylidene difluoride (Bio-Rad Laboratories)
membranes at 100 V for 1 hour. The membranes were then
blocked for 1 hour in 5% BSA in Tris-buffered saline with 0.1%
Tween 20 at room temperature. The membranes were incubated
with primary antibodies in 1% BSA at 1:1000 at 4°C overnight;
primary antibodies: AMPK, acetyl-coenzyme A carboxylase
(ACC), and phospho-AMPK (pAMPK) (Cell Signaling Tech-
nology) and pACC (Millipore), and the histamine H1 receptor
(Santa Cruz Biotechnologies, Inc). The membranes were then
washed in Tris-buffered saline with 0.1% Tween 20 (3  5 min)
and incubated with goat antirabbit (1:5000; Santa Cruz Biotech-
nologies, Inc) and horseradish peroxidase conjugated secondary
antibody at room temperature for 1 hour. Proteins were detected
with the enhanced chemiluminescence kit (GE Healthcare). Bio-
Rad Quantity One software was used to quantify the results. The
levels of protein expression were normalized to those of actin
(27). The densities of bands among the different blots were
normalized to the average band density in the control group.
Data are presented as the average density relative to the con-
trol group (27).
Statistical analysis
Statistical analysis was performed with the SPSS 19.0 pro-
gram. In experiments 1 and 2, the statistical differences of rela-
tive food intake and body weight between olanzapine and the
control group every 2 days were analyzed using the two-way
ANOVA (olanzapine  time as repeated measure) followed by
an independent unpaired Student’s t test (two-tailed). The dif-
ferences in the H1 receptor, AMPK, ACC, pAMPK, and
pACC protein expression were analyzed using an independent
unpaired Student’s t test (two-tailed). In the icv experiment (ex-
periment 3), the Kruskal-Wallis H test and then the Mann-Whit-
ney U test were used to analyze the difference in food intake. The
statistical differences of pAMPK and pACC expression were
analyzed by one-way ANOVA followed by post hoc Tukey’s
multiple comparison in the DVC. Correlations were identified
using Pearson’s correlation. All data were presented as mean 
SEM. Statistical significance was defined as P  .05.
Figure 1. Effects of olanzapine (3 mg/kgd, three times daily on (A) relative food intake (compared with control), (B) body weight, (C) feeding
efficiency, and (D) water intake, during the 36-day treatment. Rats were trained to eat cookie dough containing olanzapine or vehicle as indicated
for 36 days (see Materials and Methods) (n  12/group). All data are presented as mean  SEM. Statistical significance was defined as P  .05 (*,
P  .05; **, P  .01 vs control). FI, food intake; WG, weight gain.
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Results
Food intake, body weight, water intake, and
peripheral tissues weight
To investigate the effect of olanzapine on DVC AMPK
signaling in olanzapine-induced weight gain, rats were
treated with olanzapine or vehicle for 8, 16, and 36 days
to represent the 3 stages (26). Compared with the control
group, the olanzapine-treated group had a significantly
elevated food intake during day 4–12 (up to 40% vs con-
trol, P  .05) (Figure 1A) during the 36-day treatment.
The olanzapine treatment significantly increased body
weight from day 4 (by up to 7%, P  .05) (Figure 1B).
Feeding efficiency was significantly increased by all of the
olanzapine treatments (P  .05) (Figure 1C). Like previ-
ous studies, water intake was not altered by olanzapine
throughout the treatment period (Figure 1D) (28, 29).
There was a significant increase of sc periovary (P  .011),
perirenal (P  .032), inguinal (P  .017), and total fat
mass (periovaryperirenalinguinalomental, P 
.010) but not omental fat mass (P  .435) after 8-, 16-, and
36-day olanzapine treatments.
Olanzapine activated DVC AMPK signaling after
only 8 days of olanzapine treatment
Because the DVC AMPK plays an important role in
feeding and body weight regulation (13, 14), we investi-
gated the time-dependent effects of olanzapine on DVC
AMPK signaling by treating rats with olanzapine for 8, 16,
and 36 days. After the 8-day olanzapine treatment when
rats were hyperphagic, the protein expression of the
pAMPK and its directly downstream pACC were sig-
nificantly increased (120  6%, P  .030; 121  5%,
P  .022 vs control, respectively) (Figure 2, A, F, and H)
without changes been seen in total AMPK and ACC ex-
Figure 2. Effects of olanzapine on the protein expression of DVC AMPK signaling and the H1 receptor after 8, 16, and 36 days of olanzapine
treatment (n  5–6/group). A–C, Western blotting bands of representative DVC samples of rats treated with olanzapine or vehicle for 8, 16, and
36 days displaying bands of the H1 receptor, AMPK, pAMPK, ACC, pACC, and actin expression in the DVC. D–H, The protein expression of
the DVC H1 receptor, AMPK, pAMPK, ACC, and pACC after 8, 16, and 36 days of olanzapine or vehicle treatment. All data are presented as
mean  SEM. Statistical significance was defined as P  .05 (*, P  .05 vs control). pACC, ACC phosphorylated Ser79 at ACC-subunits;
pAMPK, AMPK phosphorylated Thr172 at AMPK-subunits.
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pression (P  .05) (Figure 2, A, E, and G) compared with
the control. Pearson’s correlation revealed that the ratio of
pAMPK/AMPK (an indicator of AMPK activity) was signif-
icantly correlated with cumulative food intake (r  0.714,
P  .014) (Figure 3A), weight gain (r  0.685, P  .020)
(Figure 3B), and feeding efficiency (r  0.615, P  .044)
(Figure 3C). These findings suggest that DVC AMPK sig-
naling may be associated with olanzapine-induced hy-
perphagia. After 16 or 36 days of olanzapine treatment,
the protein expression of AMPK, pAMPK, ACC, and
pACC in the DVC was not significantly altered (Figure 2,
B–H). Pearson’s correlation revealed that the pAMPK
expression was positively correlated with the last 48 hours
of food intake (16 days, r  0.639 and P  .034 [Figure
3D] and 36 days, r  0.655 and P  .040 [Figure 3E]),
suggesting that during long-term olanzapine treatment
(16 and 36 d), loss of AMPK activation may partially
explain why olanzapine did not increase food intake dur-
ing chronic treatment.
In the central nervous system, studies have shown that
the antipsychotic-induced activation of AMPK is related
to its antagonistic effect on the histamine H1 receptors, in
particular clozapine and olanzapine (23, 26). Olanzapine
has affinity for many receptors, including the H1 receptor,
which is significantly involved in olanzapine-induced
weight gain (30), via the regulation of AMPK signaling
(23, 26). Therefore, we examined the time-dependent ef-
fect of olanzapine on the expression of the DVC H1 re-
ceptor. We performed Western blotting to detect the pro-
tein expression of the H1 receptors. The DVC H1
receptor’s expression was not significantly altered by the
8-, 16-, and 36-day olanzapine treatments (Figure 2,
A–D). However, the DVC H1 receptor expression was
significantly positively correlated with DVC pAMPK
expression in all 3 experiments (8 days, r  0.760 and P 
.011; 16 days, r  0.671 and P  .034; and 36 days, r 
0.685 and P  .020). These correlations suggest that al-
though the H1 receptor in the DVC was not significantly
altered, it may be related to DVC AMPK signaling.
Olanzapine treatment activated the DVC AMPK
signaling in pair-fed rats
The data from the pair-feeding experiment show that
when rats consumed the same amount of food, the olan-
zapine-treated group had a similar weight gain compared
with the control group (all P  .05, n  12/group, two-
way ANOVA [olanzapine  time as a repeated measure]
[Figure 4, A and B] followed by an independent unpaired
Student’s t test). The total expression of AMPK in the DVC
was not altered by olanzapine (P  .05). Olanzapine treat-
ment significantly increased pAMPK expression (137 
11%, P  .010 vs control, n  12/group) and pACC
Figure 3. Correlations within DVC pAMPK, food intake, and weight gain after 8, 16, and 36 days of olanzapine treatment. A–C, Correlations
within the DVC pAMPK/AMPK activity, food intake, weight gain, and feeding efficiency after 8 days of treatment of olanzapine or vehicle. D and
E, Correlations within DVC pAMPK and the last 48 hours of food intake after 16 and 36 days of olanzapine treatment. All data are presented as
mean  SEM. Statistical significance was defined as P  .05. pAMPK, AMPK phosphorylated Thr172 at AMPK-subunits.
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expression (169  19%, P  .004 vs control) as well as
total ACC expression (131  12%, P  .049 vs control)
(Figure 4, C and D). Although the H1 receptor expression
was not significantly altered (P  .05), it was significantly
correlated with the expression of pAMPK (r  0.537,
P  .007, Pearson’s correlation). This evidence suggests
that the activation of DVC AMPK signaling is related to
olanzapine’s antagonistic effect on the H1 receptor.
Olanzapine-induced hyperphagia and activated
DVC AMPK were inhibited by the H1 receptor
agonist in a dose-dependent manner
We further investigated whether olanzapine’s effect on
DVC AMPK is associated with its antagonistic effect on
the H1 receptor and whether this effect is related to
olanzapine-induced hyperphagia. Olanzapine-treated rats
were given a central injection of different doses of the H1
receptor agonist, FMPH. Figure 5A shows that the olan-
zapine-treated rats receiving the saline injection (as a con-
trol) had a significantly increased food intake from 0–1
hour (by 46%, P  .020, Mann-Whitney U test), 1–2
hours (by 84%, P  .038), and 2–4 hours (by 36%, P 
.026) compared with the control rats injected with saline.
The FMPH injection attenuated the olanzapine-induced
hyperphagia in a dose-dependent manner. FMPH 200
nmol blocked the olanzapine-induced elevated food in-
take at 0–1 hour (by 64%, P  .008, Mann-Whitney U
test), 1–2 hours (by 66%, P  .083),
and 2–4 hours (by 63%, P  .007)
after the last drug treatment. FMPH
100 nmol inhibited the olanzapine-
induced hyperphagia at 2–4 hours
(by 60%, P  .004).
In terms of DVC AMPK signaling,
our data revealed significantly in-
creased pAMPK (135  5% vs V/S)
and pACC (134  7% vs V/S) ex-
pression after 5 days of olanzapine
treatment (ANOVA, F(5,31)  11.057,
P  .000; F(5,28)  5.988, P  .001,
respectively, n  5–7/group, Tukey
post hoc tests) (Figure 5, B and C).
This stimulatory effect of olanzapine
on DVC pAMPK and pACC ex-
pression was inhibited by the 200
nmol FMPH (109  5%, P  .013;
109  4%, P  .078, respectively,
Tukey post hoc tests) but not by the
100 nmol FMPH compared with sa-
line (124  3%, P  .05; 117  4%,
P  .05, respectively, Tukey post hoc
tests). Pyrilamine treatment reversed
the inhibitory effect of the 200 nmol
FMPH on pAMPK and pACC expression after the
olanzapine treatment (141  12%, P  .000; 136  7%,
P  .037, respectively, Tukey post hoc tests). An icv in-
jection of FMPH in the vehicle-treated rats did not signif-
icantly change the DVC pAMPK and pACC levels.
Moreover, the DVC pAMPK expression was also posi-
tively correlated with food intake at 1 hour (Figure 5D).
These findings indicate that the DVC AMPK appears to
regulate olanzapine-induced hyperphagia and weight gain
and that this effect is linked to olanzapine’s antagonistic
effect on the central H1 receptors.
Discussion
The present study provides the first evidence that olan-
zapine treatment time dependently affects DVC AMPK
signaling. Rats treated with olanzapine for 8 days had
significantly activated DVC AMPK signaling. However,
the DVC AMPK activation vanished with prolonged olan-
zapine treatment (16 and 36 d). During short term-olan-
zapine treatment (12 d), the rats had an elevated food
intake and rapid weight gain, consistent with previous
studies (19, 31–33). The significant correlation between
DVC AMPK activity and food intake, weight gain, and
feeding efficiency suggests that DVC AMPK signaling
Figure 4. Effects of food restriction on olanzapine-induced weight gain, DVC AMPK signaling,
and H1 receptor expression. A and B, Pair-fed rats treated with olanzapine have no significant
weight change compared with vehicle. C, The protein expression of the DVC H1 receptor,
AMPK, pAMPK, ACC, and pACC in pair-fed rats treated with olanzapine or vehicle. D,
Western blotting bands of representative DVC samples of pair-fed rats treated with olanzapine or
vehicle displaying bands of the H1 receptor, AMPK, pAMPK, ACC, pACC, and actin
expression in the DVC. pACC, ACC phosphorylated Ser79 at ACC-subunits; pAMPK, AMPK
phosphorylated Thr172 at AMPK-subunits.
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may significantly contribute to the olanzapine-induced
hyperphagia during this period. Because treatment was
prolonged, the olanzapine treatment no longer led to an
elevated food intake (3–5 wk). However, a higher body
weight was maintained compared with the control ani-
mals both in our study and data from other groups (19, 31,
33). Consistently, with food intake, long-term olanzapine
treatment did not significantly activate DVC AMPK sig-
naling, and pAMPK expression was positively correlated
with the last 48 hours of food intake. These data suggest
that during long-term olanzapine treatment, the disap-
pearance of DVC AMPK activation may at least partly
explain why long-term olanzapine treatment (2 wk) no
longer induces hyperphagia.
In addition, diet should also be considered as a factor
that influences the development of olanzapine-induced
obesity. In humans, a calorie-restricted diet has been iden-
tified to be effective for patients on olanzapine treatment
(34). Exercise and diet have improved the aerobic capacity
and body composition of obese patients treated with olan-
zapine (35). In this study, we investigated whether diet
restriction reduces olanzapine-induced weight gain and its
effect on DVC AMPK signaling. Our data show that when
energy intake is restricted, olanzapine-treated rats had a
similar weight gain compared with vehicle-treated rats
during short-term treatment. These data suggest that in-
creased energy intake may play a major role in short-term
olanzapine-induced weight gain. Restricting energy intake
may be effective for controlling olanzapine-induced
weight gain, at least during short-term treatment. Al-
though weight gain was not significantly increased, the
olanzapine treatment significantly activated DVC AMPK
signaling. These findings suggest that the olanzapine-in-
duced activation of DVC AMPK signaling is likely to be
directly caused by olanzapine treatment rather than being
a secondary effect of food intake. Moreover, it has also
been reported that male rats on a cafeteria diet (hyperca-
loric) treated with olanzapine for 4 months showed in-
creased body weight and fat pads compared with standard
diet groups (standard diet vehicle, standard diet with olan-
zapine, and cafeteria diet vehicle groups) (36). It is possible
that different diet types may also modify the effect of olan-
zapine on obesity development and other metabolic side
effects. Further studies are needed in this area.
Figure 5. Effects of an acute central injection of the H1 receptor agonist, FMPH, on olanzapine-induced hyperphagia and DVC AMPK signaling
(n  5–8/group). A, FMPH dose and time dependently inhibited the olanzapine-induced elevation of food intake. B, Effects of an acute central
injection of the H1 receptor agonist, FMPH, on DVC AMPK signaling in olanzapine or vehicle-treated rats. C, Representative Western blotting
bands of pAMPK and pACC expression in the DVC of the olanzapine or vehicle-treated rats receiving the icv injection of FMPH or saline. D,
Correlation between pAMPK expression and food intake 1 hour after the last drug treatment. All data are presented as mean  SEM. Statistical
significance was defined as P  .05 (*, P  .05; **, P  .01). H, high dose; L, low dose; PY, pyrilamine; V/F(H), vehicle/FMPH 200 nmol; O/S,
olanzapine/saline; O/F(L), olanzapine/FMPH 100 nmol; O/F(H), olanzapine/FMPH 200 nmol; O/F(H)/PY, O/F(H)/pyrilamine 800 nmol.
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In addition to regulating food intake, the fact that the
rats gain weight without hyperphagia suggests that other
factors are involved in olanzapine-induced weight gain. In
the clinic, for example, decreased energy expenditure has
been reported to be involved in the weight gain induced by
olanzapine and clozapine treatment (37–39). Previous
studies in animal models also show that SGAs, including
olanzapine and clozapine, decrease energy expenditure by
inhibiting sympathetic activity in brown adipose tissue
(BAT) (32, 40, 41). Moreover, data from our group has
reported that chronic olanzapine (36 d) treatment is as-
sociated with decreased temperature in BAT, accompa-
nied by decreased BAT uncoupling protein 1 expression
and peroxisome proliferator activated coactivator 1 ex-
pression, which are important markers of BAT thermo-
genesis (42). DVC AMPK signaling has also been shown
to be involved in regulating energy expenditure via its reg-
ulation of heart rate (14). However, the role of DVC
AMPK in BAT thermogenesis has not been fully studied.
In this study, DVC AMPK was activated by olanzapine
after the 8-day treatment but not the 16- or 36-day treat-
ments. These changes in DVC AMPK do not match the
changes in BAT temperature and uncoupling protein 1 and
peroxisome proliferator activated coactivator 1 expres-
sion. This suggests that the decreased BAT temperature
after chronic olanzapine treatment could be due to re-
duced sympathetic activity on BAT. This effect can occur
independently of olanzapine’s effect on DVC AMPK sig-
naling. Therefore, there is no association between AMPK
phosphorylation and energy expenditure in the DVC.
Mechanisms besides AMPK may be involved in olanzap-
ine-induced weight gain, for example hypothalamic NPY
and POMC (5–7).
We also investigated the mechanism by which olanzap-
ine activates DVC AMPK signaling. Olanzapine has a high
affinity for the H1 receptors, one of the major contributors
to olanzapine-induced weight gain. Previous evidence has
demonstrated that the NTS within the DVC is heavily
innervated by hypothalamic histaminergic projections
(43, 44). The NTS contains abundant H1 receptors, which
are predominantly located on neurons (44). It has been
reported in rats that the activation of the NTS H1 receptor
increases arterial pressure and heart rate (44). However,
the role of the DVC H1 receptors in food intake regulation
is unknown. Our study demonstrated that central H1 re-
ceptor activation inhibited the hyperphagia and DVC
AMPK activation induced by olanzapine. We show that
the pAMPK expression was correlated with food intake.
Therefore, it is possible that the antagonism of the DVC
H1 receptors by olanzapine may contribute to AMPK ac-
tivation in the DVC and thus increase food intake. It
would be helpful to identify the neurochemical phenotype
of neurons in the DVC that express AMPK. In addition, it
is desirable to test whether the direct activation of the DVC
H1 receptors blocks olanzapine-induced food intake and
AMPK activation.
The cross-communication of the DVC and hypotha-
lamic pathways in regulating food intake and energy bal-
ance has already been studied (45). The DVC receives pro-
jections from the hypothalamus to regulate food intake
(45). In this study, the H1 receptor agonist was injected
into the lateral ventricle (easy access to the hypothalamus).
Thus, the inhibitory effect of the H1 receptor agonist on
DVC AMPK signaling could also be an indirect effect
caused by the hypothalamus. In our previous study, we
reported that olanzapine (3 mg/kg) significantly activated
hypothalamic AMPK after an 8-day treatment (26). This
change is consistent with the change in DVC AMPK sig-
naling. However, we have performed correlation analyses
and found that pAMPK expression in the hypothalamus
and the DVC are not correlated. With prolonged olan-
zapine treatment, the hypothalamic AMPK was not acti-
vated after the 16-day treatment and was actually inhib-
ited after the 36-day treatment. These changes in DVC
AMPK signaling are not consistent with the changes in
AMPK signaling in the hypothalamus. This inconsistency
suggests that the hypothalamic and DVC AMPK may be
mediated via independent mechanisms. In fact, previous
research has reported a difference in controlling meal size
between the hypothalamus and DVC (46). The activation
of DVC AMPK signaling after the 8-day olanzapine treat-
ment may be directly caused by olanzapine’s action on the
DVC H1 receptors rather than being a secondary effect of
the hypothalamus. DVC neurons integrate multiple neu-
ropeptides and signals from the forebrain, integrate gut
and adiposity signals for long-term energy storage, and
determine food intake (8). Because DVC AMPK is an en-
ergy sensor that responds to energy status (14), the inac-
tivation of AMPK during long-term olanzapine treatment
may be caused by a negative response to energy overload.
Moreover, it has been reported that chronic olanzapine
(14 d) treatment in rats did not change ghrelin (7), DVC
NPY, or POMC expression (6), which are all important
regulators of AMPK. It is possible that the lack of DVC
AMPK activation after chronic olanzapine treatment may
be caused by multiple parameters besides the H1 recep-
tors, such as ghrelin, NPY, or POMC. Further studies are
needed.
Both hypothalamic and DVC AMPK phosphorylation
is associated with food intake in the early stages of olan-
zapine treatments. At the middle and late stages of olan-
zapine treatments, DVC but not hypothalamic AMPK
phosphorylation was still associated with food intake.
Previous studies showed that after a long-term energy
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overload, hypothalamic AMPK signaling does not play a
key role in controlling food intake (5, 47). DVC AMPK
signaling may still regulate food intake in the long-term
treatment of olanzapine. In addition, other recent studies
have shown that hypothalamic NPY, Agouti-related pep-
tide, orexin, and forkhead box protein O1 could also con-
tribute to olanzapine-induced food intake, weight gain,
and adiposity (6, 7, 48, 49). On the other hand, it is noted
that the NPY and POMC expression in the DVC was not
changed by olanzapine administration in rats (6).
Previous studies have also reported that G protein-cou-
pledreceptors, includingtheH1receptor, canbedesensitized
after a continuous activation by a receptor agonist (50–52).
There are some exceptions to this, because the serotonin 2A
receptor can be desensitized by both agonist and antagonist
exposure. Chronic olanzapine treatment causes the desensi-
tization of serotonin 2A receptor signaling and the down-
regulation of serotonin 2A receptor expression (53, 54).
Olanzapine is an H1 receptor antagonist. However, there is
no evidence to suggest that either olanzapine treatment or
other H1 receptor antagonists leads to the desensitization of
H1 receptor signaling. In the present study, H1 receptor ex-
pression is not changed by chronic olanzapine treatment,
indicating that a desensitization effect is unlikely.
In conclusion, the present study demonstrates that the
effect of olanzapine on DVC AMPK signaling varies dur-
ing different treatment periods. After short-term treat-
ment (8 d), olanzapine activated AMPK signaling, which
may contribute to olanzapine-induced hyperphagia. With
prolonged treatment, DVC AMPK was not significantly
activated, and the rats gained weight even without exces-
sive food intake, suggesting that other parameters besides
AMPK contribute to increased body weight. Central H1
receptor activation blocks DVC AMPK activation during
short-term treatment, suggesting that the antagonistic ef-
fects of olanzapine on the H1 receptor may be responsible
for the activation of DVC AMPK.
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